INTRODUCTION

Gastric cancer is the second leading cause of cancer death worldwide.\(^1\) Several risk factors for GC development have been reported, including \textit{Helicobacter pylori} infection, gastroesophageal reflux disease, and Barrett’s esophagus.\(^1,2\) Gastric cancer has a grave prognosis and the reason mainly lies in the difficulty of early diagnosis.\(^3\) Although many genes and pathways are implicated in the progression of gastric cancer, the mechanism remains largely unknown.\(^4,5\)

Abstract

Clinical reports indicate that gastric cancer (GC) has a high mortality rate, but its pathological mechanism remains poorly understood. This work integrated bioinformatics analysis with experimental verification to explore novel biomarkers of gastric cancer. First, weighted gene coexpression network analysis was applied to screen significant genes correlated with GC development. Gene set enrichment analysis was also used to unearth the most relevant biological functions of significant genes. As a result, we discovered homeobox C9 (HOXC9) as a novel oncogene in GC, primarily through negatively regulating immune response. High expression of HOXC9 predicted a poor prognosis in GC patients, and knocking down HOXC9 efficiently enhanced the interferon-gamma (IFN\(\gamma\))-dependent apoptosis in two GC cell lines as well as organoids from patients. Furthermore, cleaved caspase-3/7 and phosphorylated signal transducer and activator of transcription 1 (p-STAT1) were also significantly enhanced in HOXC9 knockdown cells and organoids treated with IFN\(\gamma\). Mechanistically, we found that HOXC9 inhibited the death-associated protein kinase 1 (DAPK1) and its downstream retinoic acid-inducible gene-1 (RIG1) to generate GC IFN\(\gamma\) resistance. In summary, we identified and confirmed that HOXC9 generates IFN\(\gamma\) resistance in GC by inhibiting the DAPK1/RIG1/p-STAT1 axis.

KEYWORDS

DAPK1/RIG1/p-STAT1, gastric cancer, HOXC9, IFN\(\gamma\) resistance, weighted coexpression network

1 | INTRODUCTION

Gastric cancer is the second leading cause of cancer death worldwide.\(^1\) Several risk factors for GC development have been reported, including \textit{Helicobacter pylori} infection, gastroesophageal reflux disease, and Barrett’s esophagus.\(^1,2\) Gastric cancer has a grave prognosis and the reason mainly lies in the difficulty of early diagnosis.\(^3\) Although many genes and pathways are implicated in the progression of gastric cancer, the mechanism remains largely unknown.\(^4,5\)
In past decades, high-throughput microarrays were widely used to identify significant genes correlated with GC development. Li et al. found COL1A1 and COL1A2 as potential GC prognostic biomarkers of GC by screening of DEGs. Ten core genes in GC tissues were also identified from four original gene chip profiles using DEG screening. Nonetheless, these studies only focused on DEGs and ignored the internal correlation. As such, a biology-related algorithm, WGCNA, was adopted to screen the significant genes correlated with clinical information in cancer and noncancer research by reanalyzing expression profiling data. For instance, Chen et al. applied this algorithm and found that CDH11 was highly correlated with prognosis and progression of GC. Nevertheless, most of these studies lacked basic experimental validation.

Interferon-gamma is proved to exert antitumor efficiency by enhancing T cell-related functions. Mechanically, IFNγ activates the JAK-STAT signaling cascade by binding with type II IFN receptor. Subsequently, the expression of IFN-induced genes mediates cell cycle arrest and apoptosis. However, not all GC patients respond well to IFNγ and the underlying mechanisms of IFNγ resistance remains largely unknown. Here, the WGCNA algorithm was used to identify hub genes significantly correlated with GC development. Eventually, HOXC9 was identified as an oncogene in GC. Furthermore, we predicted and experimentally confirmed that HOXC9 generates IFNγ resistance in GC by inhibiting the DAPK1/RIG1/p-STAT1 axis.

2 | MATERIALS AND METHODS

2.1 | Gastric cancer data study

The expression profiles of GC were obtained from TCGA and GEO databases. The WGCNA was running on a TCGA-GC cohort, which comprised 33 adjacent normal samples and 375 GC samples. The GSE13911, GSE54129, GSE66229, and GSE34942 datasets were used to validate our findings. GSE13911 included 38 GC samples and 31 normal samples. The GSE54129 dataset included 111 GC and 21 normal samples. Also, the GSE66229 dataset also included 300 GC and 100 normal samples. The GSE34942 dataset contained 56 GC with Lauren subtypes (diffuse or intestinal) and three subtypes (metabolic, proliferative, or invasive).

2.2 | Expression profile preprocessing

First, the distance of each TCGA-GC sample was evaluated by clustering in Pearson's correlation matrices (Figure S1) where no sample outlier was found. Second, the probes of the significant gene were annotated based on the corresponding platform. Finally, DEGs were screened through the “limma” R package under the cut-off of |log2-fold change| >5 and an FDR <0.05.

2.3 | Construction of WGCNA

The “WGCNA” R package was used to construct a network as previously described. All screened DEGs were used to calculate the Pearson’s correlation, and then a weighted adjacency matrix was constructed through a power function \( a_{mn} = |c_{mn}|^\beta \), where \( c_{mn} \) represents Pearson’s correlation between gene m and gene n, and \( a_{mn} \) represents adjacency between gene m and gene n. To stress the correlations between genes and penalize weak correlations, a soft threshold \( \beta \) was calculated to construct a scale-free network (Figure 1). Subsequently, a topological overlap matrix was constructed by transforming the adjacency to measure the network connectivity and adjacency. Finally, genes with similar expression profiling were classified into different gene modules by average linkage hierarchical clustering based on the gene dendrogram.

2.4 | Significant module and hub gene selection

To select a significant gene module highly associated with GC progression, the module significance and module eigengenes were calculated based on previously reported studies. Among the significant module, the gene with the highest connectivity, defined as Pearson’s correlation (cor.standard) > 0.95 and module membership (cor.weighted) > 0.60, was considered as the hub gene.

Datasets mentioned above were used to validate the role of the hub gene in GC. The “pROC” package was used to plot the ROC curve. If the area under the curve was greater than 0.7, the candidate genes were considered to be able to distinguish the normal and GC samples. The Kaplan-Meier plotter database (http://kmplot.com/analysis) was used to analyze the prognostic role of HOXC9 expression in GC. The Oncomine database (https://www.oncomine.org) was used to validate the hub gene expression in GC. The enrichment levels of the 29 immune gene sets and 28 types of immune cells in each GC sample were calculated by the ssGSEA algorithm (Tables S1, S2). The “estimate” R package was used to calculate the fraction of stromal, immune, estimate scores, and tumor purity of each sample. The heatmap was constructed using the “pheatmap” package. The relationship between HOXC9 expression and clinical phenotype was analyzed based on the MEXPRESS database. The correlation between HOXC9 and DAPK1/RIG1 was studied in the R2 database (http://r2.amc.nl) (Tumor-Gastric-u133p2-frma-192-Tang-gse15459). Gene Set Enrichment Analysis was used to explore the molecular mechanisms between low and high expression groups according to the hub gene expression under the cut-off criteria of FDR < 0.05, nominal P value < 0.05, and enrichment score > 0.5.

2.5 | Cells and reagents

Human GC cell lines SGC7901 and MKN45 were purchased from BioVector. These cell lines were maintained in RPMI-1640 (Thermo Fisher Scientific), with 1% GlutaMAX (Thermo Fisher Scientific), 1%
MEM nonessential amino acid (Thermo Fisher Scientific), and 10% FBS (Hyclone). The cells were grown in a monolayer under standard culture conditions, 5% CO₂ in a 37°C incubator. Cell identity was confirmed by short tandem repeat typing and tested for mycoplasma by PCR.

2.6 | Patients and ethics

A total of 20 GC tissues were collected from patients hospitalized at the Fourth Affiliated Hospital of China Medical University. None of the patients received radiotherapy or chemotherapy before surgery. Ethical approval was obtained from the Fourth Affiliated Hospital of China Medical University. All patients signed an informed consent form.

2.7 | Western blot analysis

MKN45 and SGC7901 cell lysate was transferred into a Triton-based lysis buffer (25 mM HEPES, 0.1 M NaCl, and 1% Triton X-100) containing protease inhibitors (Beyotime). Protein samples (20 μg) were then loaded and separated using SDS-PAGE on 8%-12% Tris-glycine gels before being transferred onto PVDF membranes at 0.2 A for 120 minutes. Following this, the membranes were blocked with western blocking buffer (Beyotime) for 2 hours at 37°C. Subsequently, the membranes were immunoblotted at 4°C overnight using anti-RIG1 (1:1000 dilution; CST), anti-β-actin (1:2000 dilution; CST), anti-DAPK1 (1:2000 dilution; CST), anti-p-STAT1 (1:2000 dilution; CST), anti-STAT1 (1:2000 dilution; CST). After washing four times with TBST, the membranes were incubated with the HRP-coupled Abs (1:3000 dilution; CST) for 90 minutes. The membranes were washed four times with TBST again and visualized by enhanced chemiluminescence according to the manufacturer’s protocol (ECL kit; Beyotime).

For protein IP, SGC7901 cells were lysed with IP buffer (Beyotime) by incubating for 30 minutes at 4°C. Coimmunoprecipitation was carried out with whole-cell lysates using co-IP buffer. Either nuclear or whole-cell lysates were incubated overnight with STAT1 Abs (1:100 dilution; CST) then for 1 hour with appropriate Dynabeads the following day. Bound proteins were eluted with co-IP buffer for 10 minutes at 100°C before SDS-PAGE analysis.
2.8 | Chromatin IP PCR

For ChIP, cells were fixed with 1% formaldehyde at room temperature for 5 minutes to establish DNA-protein cross-links. Glycine (125 mM) was added to stop the cross-linking and incubated at room temperature for 10 minutes. Cells were washed three times with cold PBS for 5 minutes. One milliliter of cell lysis containing protease inhibitors (MCE) was added to suspend cells and then cell lysates were sonicated using the EpiSonic sonication system to obtain 200-400 bp of chromatin fragments. Chromatin immunoprecipitation was undertaken using the ChIP Assay Kit (P2078; Beyotime). The purified DNA was extracted using a DNA purification kit (Tiangen) and then subjected to quantitative PCR for DAPK1 promoter detection.

2.9 | Dual luciferase reporter assay

Dual luciferase reporter assays were carried out in a Modulus II Microplate Multimode Reader (Turner Biosystems). A Dual-Lumi Luciferase Assay System was used following the manufacturer’s instructions (Beyotime). Briefly, Dual-Lumi luciferase substrate was added to each well. After 15 minutes of incubation, the firefly luminescence signal (Fluc) was recorded using a plate reader. Then the stop substrate was added for a second incubation of 10 minutes, and the Renilla luciferase signal (Relina-Luc) was recorded. Finally, the results were analyzed by calculating the ratio of luminescence from the experimental reporter to the luminescence from the control reporter and normalized to control wells.

2.10 | Immunofluorescence staining

Derived organoids from patients were fixed in 4% paraformaldehyde for 96 hours and were sliced into 5-μm-thick sections. After being deparaffinized and rehydrated in alcohol and water, antigen retrieval was carried out in sodium citrate buffer at 100°C for 5 minutes. Hydrogen peroxide (0.3%) was used to block peroxidase. Sections were incubated with primary Abs, including anti-RIG1 (1:200; Abcam), anti-DAPK1 (1:200 dilution; CST), and anti-RIG1 (1:200 dilution; CST), at 4°C overnight. After washing with PBST for 15 minutes, samples were incubated with goat anti-rabbit or mouse secondary Ab (1:3000 dilution; CST) and nuclei were stained with DAPI (Beyotime). Images were obtained under a laser scanning confocal microscope (Nikon).

2.11 | Organoid culture

The isolated GC tissue segments were washed three times with cold PBS for 5 minutes and cut open longitudinally. After washing the PBS, the segment was cut into 2-mm pieces. The pieces were digested with collagenase (1 mg/mL collagenase; Sigma Aldrich) in Ady DMEM/F-12 (12634028; Thermo Fisher Scientific) with ROCK inhibitor (Y-27632; 10 μM) for 2 hours at 37°C, followed by collection of the supernatant through a 70-μm filter, which was repeated three times. Patient-derived organoids were cultured in HOM. The composition of HOM included advanced DMEM with 20% R-spondin conditioned medium, 10% Noggin conditioned medium, 1 x B27 (Thermo Fisher Scientific), 1.25 mM N-acetyl cysteine (Selleck Sciences), 10 mM nicotinamide (Selleck Sciences), 50 ng/mL human epidermal growth factor (Selleck Sciences), 500 mM A83-01 (Selleck Sciences), and 10 μM ROCK inhibitor (Selleck Sciences). Derived organoids from patients were fixed in 4% paraformaldehyde for 96 hours and sliced into 5-μm-thick sections. After being deparaffinized and rehydrated in alcohol and water, the sections were subjected to conventional H&E staining. The images were observed under a microscope (Olympus, IX83) to determine the pathological changes of the brain tissues.

2.12 | Overexpression and stable KO construction

To establish HOXC9-, DAPK1-, or RIG1-overexpressing cells, SGC7901 and MKN45 cells were transfected with Lipofectamine3000 reagent (Invitrogen). The pCMV-HOXC9, pCMV-DAPK1, and pCMV-RIG1 vectors were purchased from Sinobiological. Cells were selected with 500 μg/mL G418 (Beyotime) and KO efficiency was determined by western blot analysis.

To establish HOXC9, DAPK1, and RIG1 knockdown cells, SGC7901 and MKN45 cells were transfected with Lipofectamine3000 reagent (Invitrogen) and siRNA. The siRNAs were purchased from Tsingke. The siRNA sequences were as follows: HOXC9 si-1, 5′-CGTGCCCTCTCTCA GTCGTCCGTGGA-3′; HOXC9 si-2, 5′-CCGTCGTTATGAGGTGGCC CGGGTTT-3′; DAPK1 si-1, 5′-GGGGCCGAGGCTGGCAGGCTGG -3′; DAPK1 si-2, 5′-CCGGTCCGGCGAGCTGAGAGAGAT-3′; RIG1 si-1, 5′-CTGCTATATGTGAAACATCCTTAA -3′; and RIG1 si-2, 5′-CC ACAGATTCTTGTGAAACACCTTA-3′.

To establish HOXC9 knockdown cells, SGC7901 and MKN45 cells were transfected with Lipofectamine3000 reagent (Invitrogen). The PLKO.1-Puro vectors were purchased from GenePharma. The shRNA sequences were as follows: HOXC9 sh1, 5′-CCGGCCCGCA GCATCCGGGAATCTACATCCAGATGTTGGCAGTTAGCTGGG TTGGTTTT-3′; HOXC9 sh2, 5′-CCGGCCCGGTGCTTCTAATCCTACCA CGCTGACTCGTGAGATTGAACGAGCAGGGTTTTTT-3′; and ShCtrl, 5′-GGAATCTCATTGCATGCATAC-3′.

2.13 | Cell viability assay

Cell viability was analyzed using CCK-8 assays. Gastric cancer cells were seeded at 10 000 cells per well in a 96-well plate, and CCK-8 solution was added in the wells and incubated at 37°C for 2 hours. The absorbance value (optical density) was measured at 490 nm
using a microplate reader (ELx800; BioTek). Each experiment was repeated at least three times.

2.14 | Prediction of ICI treatment response

We used the TIGER database (http://tiger.canceromics.org/#/home) to show the HOXC9 expression between responders and nonresponders in several melanoma ICI-treated cohorts (N ≥ 10). In addition, to predict the correlation between HOXC9 and ICI treatment in GC, we applied the SubMap analysis (Gene Pattern). This bioinformatics method helped identify genetic similarity in gene expression profiles between subgroups from different independent cohorts. Thus, we used this algorithm to measure the similarity of HOXC9-high and HOXC9-low groups with different groups of patients from one melanoma ICI cohort.

2.15 | Statistical analysis

In this study, statistical analyses were undertaken using R 3.6.1 software and GraphPad Prism 7.0. Data were expressed as the means ± SEM. Comparisons between two groups were carried out by unpaired Student’s t test or one-way ANOVA. Correlations between groups were determined by Pearson’s correlation test. Survival rates were analyzed by the Kaplan-Meier method. The sample number (n) indicates the number of independent biological samples in each experiment. Generally, all experiments were carried out with n ≥ 3 biological replicates. P < .05 was considered statistically significant.

3 | RESULTS

3.1 | Red module as the significant module and HOXC9 as the hub gene

A total of 9376 DEGs were run for the WGCNA analysis and the soft threshold was calculated as 5 for scale-free network construction (Figure 1). As shown in Figure 2A, all DEGs were divided into 11 gene modules (Figure 2A). Among these modules, the red module showed both the highest module significance and module eigengene (Figure 2B,C). Therefore, genes in the red module were selected for further screening of hub genes. HOXC9 was selected as the hub gene because of the highest cor.weighted and cor.standard (excluding the first noncoding RNA). Table 1 shows the genes based on both weighted and standard correlation coefficients. Collectively, our data predicted HOXC9 as the most significant gene associated with GC progression.

3.2 | Upregulation of HOXC9 in GC

In the test databases of GEO and Oncomine, HOXC9 expression was significantly upregulated in GC samples compared to that in adjacent normal samples (Figure 3A,B). The ROC analysis indicated that HOXC9 expression effectively distinguished GC from normal gastric tissues based on the TCGA database (Figure 3C). Furthermore, in the test set of GSE34942, HOXC9 expression was significantly upregulated in the proliferative subtype compared to the metabolic and invasive subtypes, whereas there were no
significant difference between diffuse and intestinal subtypes (Figure 3D). The survival analysis found that high HOXC9 expression showed a poor prognosis of OS, FP, and PPS in GC patients (Figure 3E). Nevertheless, HOXC9 expression was not associated with clinical phenotype based on the public MEXPRESS database (Figure S2).
3.3 | Negative regulation of immune response in GC by HOXC9

To identify potential biological functions of HOXC9, GSEA was applied. Eight gene sets associated with inflammatory response were finally enriched, including "allograft rejection," "inflammatory response," "interferon gamma response," "IL2 STAT5 signaling," "IL6 JAK STAT3 signaling," "TNFA signaling via NFkB," "UV response DN," and "epithelial mesenchymal transition" (Figure 4A). Moreover, we applied several published immune-related tools to decipher the immune heterogeneity between HOXC9-high and HOXC9-low expression groups. First, we computed the stromal and immune score of each group by the "estimate" R package. The results showed that lower levels of stromal, immune, and estimate scores were found in the HOXC9-high expression group (Figure 4B). A reduction of tumor purity was also observed in the HOXC9-high group (Figure 4B), indicating that this group might contain low levels of immune cells. It was found that higher HOXC9 showed a high negative correlation with these scores (Figure 4C). The ssGSEA algorithm further confirmed that patients in the HOXC9-high expression group showed lower fractions of 29 immune-related functions (Figure S3). These data indicated that high HOXC9 expression could promote the formation of cold tumor microenvironment.

To clarify the relationship between the high expression of HOXC9 and the formation of cold tumors, we analyzed 28 immune cells in the tumor microenvironment. The heatmap showed that almost all immune cells had significantly reduced infiltration in the HOXC9-high expression group (Figure 4D). Furthermore, the "limma" analysis results showed that, among the immune cells with significantly reduced infiltration in the HOXC9-high expression group, the top seven with the most significant fold change were mainly T cells, including Type 1 helper, central memory CD8 T, effector memory CD4 T, natural killer, and effector memory CD8 T cells (Figure 4E). Therefore, these data indicated that high HOXC9 expression could form cold tumors by inhibiting the activation of T cells.

3.4 | Knockdown of HOXC9 expression increased IFNγ-dependent apoptosis

To further evaluate the role of HOXC9 in GC, the HOXC9 expression in SGC7901 and MKN45 cells was silenced by siRNA (Figure 5A). Consequently, knockdown of HOXC9 effectively enhanced IFNγ-dependent apoptosis (Figure 5B,C). However, overexpression of HOXC9 impaired IFNγ-dependent apoptosis (Figure 5A), indicating that HOXC9 acted as the downstream molecule of IFNγ to induce GC cells apoptosis. To further demonstrate our data in vivo, we established PDOs. Intriguingly, we found that GC tissues with high HOXC9 levels had IFNγ resistance (Figure 5D-F). More importantly, a high correlation was observed between HOXC9 level and IFNγ-induced apoptosis (Figure 5G), corroborating the findings in the cell line. As a member of the STAT family, STAT1 is an essential component of IFN signaling that mediates several cellular functions in response to CD8 T cells. Here, upregulation of p-STAT1 and cleaved caspase-3/7 were observed in HOXC9 KO cell lines (Figure 5H). Consistently, overexpression of HOXC9 impaired the IFNγ-dependent upregulation of p-STAT1 and cleaved caspase-3/7 (Figure 5I). More importantly, a high negative correlation was observed between HOXC9 and p-STAT1 levels (Figure 5J). Collectively, these findings indicate that HOXC9 negatively regulates the IFNγ signaling pathway in GC cells and PDOs, inducing resistance of GC cells to IFNγ.

3.5 | HOXC9 induced IFNγ resistance by downregulating DAPK1/RIG1 expression

Next, we investigated the molecular pathway through which HOXC9 repressed cancer immunity in GC. Previous data revealed that HOXC9 directly inhibited the transcription of DAPK1, and knockdown of DAPK1 attenuated RIG1 expression, a cytosolic pattern recognition receptor that initiates innate antiviral immunity and cancer immunotherapy. Consistently, upregulation of DAPK1 and RIG1 were observed in SGC7901 and MKN45 cells transfected with HOXC9 siRNA (Figure 6A). Moreover, our ChIP and dual-luciferase analyses showed that HOXC9 was enriched in the promoter sites of DAPK1 and inhibited DAPK1 expression (Figure 6B,C), confirming that HOXC9 might attenuate DAPK1 activation and negatively regulate RIG-I expression.

Previous studies have reported RIG1 amplifies IFN-JAK-STAT effector signaling by diminishing the interaction between SHP1 and STAT1 in cancer cells. We also confirmed that RIG1 and STAT1 interact with each other with or without IFNγ using IP. Moreover, we found that SHP1 was coimmunoprecipitated with STAT1, but this interaction was increased by RIG1 KO (Figure 5F). ClusPro server was used to estimate protein-protein interaction. We found that there might be interaction domains between RIG1 and STAT1 (Figure 5D). Hence, RIG1 promotes STAT1 activation mainly through suppressing the interaction and inhibition of STAT1 by SHP1 and competitively binding STAT1.

To further confirm the role of the HOXC9-DAPK1-RIG1 axis in IFNγ resistance, we knocked out DAPK1 or RIG1 in HOXC9-silenced SGC7901 and MKN45 cell lines by siRNA (Figure 6D,E). Consistently, we found that RIG1 was significantly downregulated in GC cells with knocked out DAPK1 (Figure 6D). Intriguingly, DAPK1 or RIG1 KO efficiently reversed the SGC7901 and MKN45 sensitivity to IFNγ induced by silencing HOXC9 (Figure 6F). Similar results were observed in PDOs (Figure 6G). Importantly, DAPK1 or RIG1 KO also efficiently inhibited the expression of p-STAT1 in SGC7901 and MKN45 cells, induced by IFNγ (Figure 6H,I). Consistently, reconstitution of HOXC9 in HOXC9-silenced cells can downregulate RIG1 expression. In contrast, the overexpression of DAPK1 can impair HOXC9-mediated RIG1 downregulation (Figure 5E). To further support the correlation between HOXC9 and DAPK1/RIG1 in vivo, we analyzed the R2 online database (http://r2.amc.nl) and found that HOXC9 was
FIGURE 4 | High expression of HOXC9 inhibits immune microenvironment in gastric cancer (GC). A, Gene Set Enrichment Analysis plots of significant gene sets showing positive correlation with higher expression of HOXC9 in The Cancer Genome Atlas (TCGA) cohort. B, Comparison of ImmuneScore, StromalScore, ESTIMATEScore, and TumorPurity between HOXC9-high and HOXC9-low expression groups. C, Correlation between HOXC9 expression and immune scores, stromal scores, estimate score, and tumor purity in the TCGA cohort. D, Heatmap showing the difference in 28 types of immune cells between high- and low-HOXC9 groups of the TCGA cohort. E, Bar graph showing the median level of the 28 regulated immune cells infiltrating high vs low HOXC9-expressing GC samples based on the TCGA cohort. *P < .01, **P < .001, ***P < .0001

FIGURE 5 | Knockdown of HOXC9 expression increased interferon-gamma (IFNγ)-dependent apoptosis. A, Western blot assay of HOXC9 expression in SGC7901-shNC, SGC7901-sh1, SGC7901-sh2, MKN45-shNC, MKN45-sh1, and MKN45-sh2 cells. B, After treatment with IFNγ (100 ng/mL) for 48 h, SGC7901-shNC, SGC7901-sh1, and SGC7901-sh2 cells were isolated, stained with annexin V and propidium iodide (PI) and analyzed by flow cytometry for apoptosis detection. C, After treatment with IFNγ (100 ng/mL) for 48 h, MKN45-shNC, MKN45-sh1, and MKN45-sh2 cells were isolated, stained with annexin V and PI, and analyzed by flow cytometry for apoptosis detection. D, H&E staining and cell microscope photographs of patient-derived organoids (PDOs) with HOXC9-high and -low expression treated with IFNγ (100 ng/mL) for 48 h. Bar = 25 μm. E, After treating with IFNγ (100 ng/mL) for 48 h, PDOs with HOXC9-high and -low expression were isolated, stained with annexin V and PI, and analyzed by flow cytometry for apoptosis detection. F, Confocal images of PDOs with HOXC9-high and -low expression. Bar = 25 μm. G, Pearson’s correlation of HOXC9 expression and the apoptosis rate. H, SGC7901-shNC, SGC7901-sh1, SGC7901-sh2, MKN45-shNC, MKN45-sh1, and MKN45-sh2 cells were treated with PBS or IFNγ (100 ng/mL) for 48 h. Cell lysates were collected and phosphorylated STAT1 (p-STAT1), cleaved-caspase-3, and cleaved-caspase-7 were analyzed by western blot. β-Actin was used as internal reference. I, PDOs with HOXC9-high and -low expression were treated with PBS or IFNγ (100 ng/mL) for 48 h. PDOs were then washed with PBS and cell lysates were collected and p-STAT1, cleaved-caspase-3, and cleaved-caspase-7 were analyzed by western blot. β-Actin was used as internal reference. J, Pearson’s correlation of HOXC9 expression and p-STAT1 expression. *P < .05, **P < .01, ***P < .001, ****P < .0001

significant negatively correlated with DAPK1 (r = −.242, P = 4.14e-04) and RIG1 (r = −.314, P = 9.01e-06), while DAPK1 was significantly positively correlated with RIG1 (r = .328, P = 3.49e-06) (Figure S5). These results suggested that HOXC9 downregulated the expression of DAPK1 downstream molecule RIG1 to induce the development of GC IFNγ resistance.

3.6 | Downregulation of HOXC9 predicted a promising response to anti-PD-1 therapy

Finally, we explored the correlation between HOXC9 expression and sensitivity to therapy using ICIIs. Based on the TIGER database,
we compared the HOXC9 expression between responders and nonresponders in several melanoma ICI-treated cohorts (n ≥ 10). In the GSE91061 and phs000452 datasets, we found that the responders showed lower levels of HOXC9 expression (Figure 7A,B). Furthermore, in the PRJEB23709 dataset, HOXC9 expression decreased significantly in the responder group, especially when anti-PD-1 was used alone (Figure 7C,D). However, we found that there was no significant difference in HOXC9 expression when anti-CTLA4 and anti-PD-1 were used in combination (Figure 7E). Interestingly, male patients seem to have a more significant decline in HOXC9 expression, although there was no statistical difference (Figure 7B,D). To better clarify the relationship between HOXC9 expression and immunotherapeutic response in GC, we used the SubMap algorithm and found that patients with low HOXC9 expression could be more sensitive to anti-PD-1 therapy (Bonferroni-corrected P = .024). Taken together, our findings indicated that HOXC9 could be a new biomarker for anti-PD-1 therapy.

4 | DISCUSSION

Through WGCNA, this study identified HOXC9 as a novel onco-gene, which highly correlated with the progression and prognosis of GC. The GSEA results further revealed that HOXC9 could negatively regulate immune response. Regarding validation, knockdown of HOXC9 expression effectively enhanced IFNγ-dependent apoptosis in SGC7901 and MKN45 cells and PDOs. Furthermore, cleaved caspase-3/7 and p-STAT1 were significantly enhanced in HOXC9 knockdown cells and organoids treated with IFNγ. Mechanistically, we found that HOXC9 inhibited DAPK1 and the downstream RIG1 to generate GC IFNγ resistance.

Of note, HOXC9 belongs to the homeobox transcription factor family, which is implicated in cell cycle, differentiation, migration, and other biological processes. Thus, the dysregulation of HOXC9 expression is strongly linked to multiple malignant tumor progression, including colorectal cancer, breast cancer, and glioblastoma. Furthermore, Zhao et al reported significant upregulation of HOXC9 expression in GC compared to normal tissues. Similarly, based on public databases, our findings confirmed that HOXC9 was an oncogene in GC. Moreover, we found that patients with higher expression level of HOXC9 predicted a poor prognosis in terms of OS, FP, and PPS, indicating HOXC9 was an unfavorable prognosis factor in GC.

Next, we explored the molecular mechanism of HOXC9 promoting GC progression. Peng et al reported that upregulation of microRNA-26a induced metastasis and self-renewal through downregulated HOXC9. Based on the GSEA results, this work indicated that HOXC9 was highly and negatively correlated with immune response. Furthermore, the high HOXC9 group revealed low levels of immune-related biological functions compared to the low HOXC9 group. At present, information on the relationship between HOXC9 and tumor immunity remains unreported. Nonetheless, it was evident that other members of the HOX family modulated inflammatory responses in multiple types of cancers. For example, upregulation of HOXB9 expression induced higher levels of IL-8 in breast cancer, which was related to tumor development. Also, HOX9 inhibited innate immune response by suppressing the nuclear factor-xb (nf-xb) pathway. As such, for the first time, we reported the immunomodulatory mechanism of HOXC9 in GC.

Accumulating evidence has implicated effective T cell response in patients who temporarily benefit from surgical resection and/or chemotherapy. Remarkable response rates for PD-1 or other immunotherapies have been reported in the treatment of GC. Unfortunately, not all patients benefit equally from immunotherapy. Primary or acquired immunotherapy resistance is a primary concern, thus, the understanding of resistance mechanisms is critical for advancing GC treatment. Additionally, IFNγ plays a critical role in an antitumor effect through extrinsic or tumor cell-intrinsic mechanisms. Concerning the extrinsic antitumor property, IFNγ promotes antitumor immunity and stimulates tumors to infiltrate immune cell recognition and elimination. Regarding the tumor cell-intrinsic mechanism, studies showed that IFNγ exerts a strong antitumor role by promoting growth arrest and cell death through p-STAT1 signaling. More importantly, resistance to immunotherapy has been attributed to mutated IFNγ signaling, as well as IFNγ resistance protecting from cytokine-induced cell cycle arrest/apoptosis. In the present study, we found that the expression of HOXC9 also induced the IFNγ resistance phenotypes of GC cells in cell lines and PDOs by suppressing phosphorylation of STAT1. We also found that downregulation of DAPK1 signaling induced by HOXC9 caused...
FIGURE 7  Correlation between HOXC9 expression and immunotherapeutic response. A, TIGER database (http://tiger.cancermics.org/#/home) showed HOXC9 expression between responders (R) and nonresponders (NR) in the anti-programmed death-1 (PD-1) GSE91061 cohort. B, TIGER database showed HOXC9 expression between R and NR in the anti-PD-1 phs000452 cohort. C, TIGER database showed HOXC9 expression between R and NR for all treatment in the PRJEB23709 cohort. D, TIGER database showed HOXC9 expression between R and NR for anti-PD-1 in the PRJEB23709 cohort. E, TIGER database showed the HOXC9 expression between R and NR for anti-CTLA4+anti-PD-1 in the PRJEB23709 cohort. F, SubMap analysis of the HOXC9-high and -low expression groups in The Cancer Genome Atlas gastric cancer cohort and four groups (anti-PD-1 responsive [-R] and nonresponsive [NR], and anti-CTLA-4-R and -NR) in a melanoma cohort treated with immune checkpoint inhibitors
an enhanced resistance to apoptosis by IFN\(\gamma\) signaling. Additionally, the DAPK1 downstream tumor suppressor gene RIG1 was downregulated, causing IFN\(\gamma\) resistance in GC treatment.

In conclusion, we identified and verified that HOXC9 played an oncogenic role by inhibiting immune response in the GC immune microenvironment. Mechanistically, HOXC9 exerted IFN\(\gamma\) resistance by downregulating the DAPK1/RIG1/p-STAT1 axis in GC. Downregulated expression of HOXC9 might sensitize cells to IFN\(\gamma\). Our findings showed that the molecular mechanism of HOXC9 provided a novel immunotherapeutic biomarker for GC in the future.

ACKNOWLEDGMENT
This work was supported by a grant from the young and middle-aged scientific and technological talents support program of Shenyang City (No. RC200554 to Chunli Wu).

CONFLICT OF INTEREST
None declared.

ORCID
Chunli Wu https://orcid.org/0000-0003-1809-6752

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487-90.
3. Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622-628.
4. Chen PF, Wang F, Nie JY, et al. Co-expression network analysis showed that the molecular mechanism of HOXC9 might sensitize cells to IFN\(\gamma\). Our findings showed that the molecular mechanism of HOXC9 provided a novel immunotherapeutic biomarker for GC in the future.

For the remaining references, please refer to the provided PDF or online source.
35. Pai P, Sukumar S. HOX genes and the NF-κB pathway: a convergence of developmental biology, inflammation and cancer biology. Biochim Biophys Acta. 2020;1874:188450.

36. Hayashida T, Takahashi F, Chiba N, et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA. 2010;107:1100-1105.

37. Irazoqui JE, Ng A, Xavier RJ, Ausubel FM. Role for beta-catenin and HOX transcription factors in Caenorhabditis elegans and mammalian host epithelial-pathogen interactions. Proc Natl Acad Sci USA. 2008;105:17469-17474.

38. Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45-56.

39. Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies. Am Soc Clin Oncol Educ Book. 2016;35:450-458.

40. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635-648.

41. Akin Telli T, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Lett. 2020;469:142-150.

42. Coutzac C, Pernot S, Chaput N, Zaanan A. Immunotherapy in advanced gastric cancer, is it the future? Crit Rev Oncol Hematol. 2019;133:25-32.

43. Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28:1767-1775.

44. Zayac A, Almhanna K. Esophageal, gastric cancer and immunotherapy: small steps in the right direction? Transl Gastroenterol Hepatol. 2020;5:9.

45. Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545-558.

46. Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7:4509-4516.

47. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127:2930-2940.

48. Yang S, Wei J, Cui YH, et al. m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10:2782.

49. Dosset M, Vargas TR, Lagrange A, et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7:e1433981.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.